<DOC>
	<DOCNO>NCT01907776</DOCNO>
	<brief_summary>This single-center , randomize , double-blind , placebo-controlled , sequential group study . The primary objective study assess tolerability safety single dos ME1100 inhalation solution ( orally inhale arbekacin ) . The secondary objective determine systemic exposure , urinary elimination , ME1100 .</brief_summary>
	<brief_title>Pharmacokinetics Safety Study ME1100 Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Habekacin</mesh_term>
	<criteria>Male ( surgically sterile agree practice barrier contraception throughout participation study ) Female ( use oral double barrier contraceptive sexually active , surgically sterile postmenopausal confirm follicle stimulation hormone test ) ; Willing give write informed consent 18 55 year age time consent Body Mass Index 1830 kg/m2 Nonsmoker ( least 6 month prior screen ) willing abstain smoking course study Good general health determine medical history , physical examination , 12lead electrocardiogram clinical laboratory test ( include normal renal function high frequency audiometry ) Willing abstain alcohol , caffeine , xanthinecontaining beverage 24 hour prior 72 hour dose . Japanese subject must first generation Japanese ( 4 grandparent , biologic parent subject born Japan ) Uncontrolled , clinically significant disease opinion Principal Investigator Medical Monitor would place subject risk study participation would confound assessment safety ME1100 inhalation solution Evidence current history respiratory disease , include asthma , emphysema , chronic bronchitis , cystic fibrosis History current symptom ( ) respiratory tract inflammation within 30 day Visit 2 History hearing , balance ear disorder surgery injury ear , genetic mutation ( &gt; 5.0 % heteroplasmy ) suggestive increase risk hearing loss ( MTRNR1 [ A1555G ] mitochondrial 12S ribosomal RNA gene MTTS1 [ A3243G ] mitochondrial transfer RNA serine 1 ) History parent , sibling parental sibling report hearing loss age 65 year History malignancy History clinically significant alcohol drug abuse History within last 6 month current use tobacco product include ecigarettes Positive drug screen drug abuse Positive test HIV , Hepatitis B Hepatitis C Use prescription overthecounter medication ( except oral hormonal contraceptive ) , herbal supplement , vitamin within 14 day Visit 2 Known hypersensitivity aminoglycoside bacitracin antibiotic Female childbearing potential positive urine pregnancy test , currently breast feed . Inability perform reproducible spirometry accordance American Thoracic Society ( ATS ) guideline Abnormal Forced Expiratory Volume First Second ( FEV1 ) , Forced Vital Capacity ( FVC ) , FEV1/FVC ( FEV1 FVC &lt; 80 % predict FEV1/FVC ratio &lt; 0.7 ) FEV1 variability &gt; 10 % Visit 1 Visit 2 ( prior dosing ) Significant blood donation ( test ) previous 8 week screen . Use Investigational Product previous 30 day 5 halflives , whichever longer , precede start screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>